Company ProfilePremium

Chunbo Co., Ltd.

Company Profile Analysis

Ticker: 278280.KQ주식회사 천보

ESOMAR 23 Corporate BadgeISO Certifications Badge
Chunbo Co., Ltd. - Company showcase

Year Founded & Workforce

1997

Chunbo Co., Ltd. logo

Chunbo Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Chunbo Co., Ltd. Overview

Chunbo is a Korean fine-chemical synthesis and purification company. It has moved from niche display and semiconductor process chemicals to specialty lithium salts and electrolyte additives for lithium-ion batteries. Its main technical claim is that it was the first company worldwide to commercialize LiFSI (the "F-electrolyte"). Sources date this to 2016 or 2017. It also makes LiPO2F2 (the "P-electrolyte"), on which Korean battery-cell export volumes have tracked its revenue closely, together with LiDFOP, LiBOB and a broad range of film-forming additives (VC, FEC, PS, ESA and others). A smaller electronic-materials franchise (LCD etchant additives, OLED common-layer materials, semiconductor process chemicals, oxalic acid) supplies most of the operating profit at around 20% margins. Since 2021 the company has spent heavily on a greenfield LiFSI and additive complex in Saemangeum through subsidiary Chunbo BLS, financed largely with mezzanine capital. The 2023–2025 downturn in electrolyte prices, combined with plant delays, eliminated profits. The 2026 investment case depends on ramping LiFSI supply to a North American OEM's 4680 cell program and on a recovery in Chinese electrolyte demand.


What the company does

Chunbo is a specialty-chemical manufacturer working in three technology domains that its IR material calls IT, BT and GT. In its own descriptions it supplies:

  • additives used in manufacturing LCD and OLED display panels;

  • raw materials for EMC (epoxy molding compound) resins;

  • semiconductor process materials;

  • oxalic acid;

  • pharmaceutical raw materials and intermediates;

  • secondary-battery materials (lithium salts and electrolyte additives);

  • other specialty chemicals, including tire additives and materials for chemically strengthened display glass.

Source: company description as summarized by StockHub and Kiwoom (2026); Chunbo IR decks 2022–2024.

The company describes itself as a "comprehensive precision chemical materials company." In a 2023 investor meeting, its CFO said the company's real identity is fine chemicals: it is strong in synthesis and purification, it often holds first-mover or near-monopoly positions in the molecules it makes, and its products have historically carried market shares near 90% with operating margins near 20% (Digital Daily, 30 Apr 2023). Third-party profiles also call Chunbo Korea's only oxalic-acid producer, supplying Korean chipmakers and exporting to Japan and Taiwan, and the world's largest producer of 5-aminotetrazole (ATZ) (Innoforest company profile).

Business model and revenue model

The revenue model is product-based and B2B: it sells high-purity chemicals by weight under supply agreements. There is no material service, subscription or licensing revenue disclosed. Key features:

Battery materials (~51–58% of revenue): Lithium salts and additives are sold to electrolyte makers and battery-cell makers. Pricing is linked partly to lithium carbonate and LiPF6 market prices, which caused the 2023–2024 collapse in average selling prices. Broker research in late 2025 and 2026 points to price pass-through clauses: Mirae Asset expected roughly 20% pass-through of raw-material increases into selling prices from H2 2026 (Mirae Asset via HelloT, 13 Apr 2026).

Electronic materials (~29–38%): Etchant additives, OLED intermediates and semiconductor chemicals are qualified into specific customer processes. This creates high switching costs and stable margins; Mirae Asset cites operating margins around 20% (Apr 2026).

Pharma intermediates, fine chemicals and other (~8–13%): Custom synthesis and catalog chemicals, including ATZ and oxalic acid.

Value-chain position

In the battery chain, Chunbo sits upstream of electrolyte formulators (e.g., Dongwha Electrolyte, Enchem, Soulbrain, and Chinese formulators) and battery-cell makers. It supplies the functional salts and additives, typically a few percent of electrolyte weight, that set cycle life, high-voltage stability, low-temperature performance and safety. LiFSI can also be used as a co-salt alongside, or partial replacement for, LiPF6. In display and semiconductor chains it is a tier-2 or tier-3 chemical supplier to panel makers, chemical formulators and fabs.

Customer types and end-markets

End-marketCustomer typesNamed customers (as disclosed or reported)Source
EV and ESS batteriesCell makers; electrolyte formulatorsLG Energy Solution, Samsung SDI, SK On, CATL, BYD, Panasonic, TeslaCFO remarks, Digital Daily (30 Apr 2023)
EV batteries (2020-era)Cell makersLGES, Samsung SDI, SK Innovation, CATL; the batteries went into BMW i3/i8, Chevrolet Volt, VW e-GolfTheElec (25 Jan 2021)
China (2025–26)Cell makersEVE Energy (LiPO2F2 volume growth in Q4 2025)Kiwoom (2 Jan 2026)
North American OEMOEM in-house cell productionF-electrolyte shipments since early 2026, believed by Mirae Asset to go to Tesla's 4680 cells for the CybercabMirae Asset via HelloT (13 Apr 2026); Kiwoom (27 Aug 2026)
DisplayPanel makers and etchant formulatorsNot named in sources—
SemiconductorsKorean chipmakers (oxalic acid, process chemicals)Not namedInnoforest
PharmaPharmaceutical companiesNot namedStockHub/company description

Independent characterization

Chunbo is a capable small-molecule chemist that made a large, debt-financed bet on a single application. Battery materials grew from about KRW 2bn of revenue in 2015 (Hana Financial Investment, cited by Asia Economy, Oct 2018) to around 68% of group revenue by 2022 (Dealsite, 25 Apr 2023). That transformed Chunbo from a steady mid-teens-margin specialty house into a cyclical, capital-intensive battery-materials company. Three things then went wrong at once: the 2023–2024 lithium price collapse, Chinese overcapacity in LiFSI and additives, and delays at the Saemangeum plant. Together they turned an operating margin of 17–19% (FY2021–FY2022) into losses (FY2023–FY2024). Since 2025 the business has returned to marginal operating breakeven. Net losses continue, driven by non-cash derivative losses on convertible bonds and by interest. The electronic-materials franchise is the stable core that partly subsidizes the battery ramp.

Strategy

Stated strategic themes (paraphrased from IR materials and management remarks)

  1. Leadership in next-generation lithium salts. Scale LiFSI as the successor or co-salt to LiPF6 and hold leading positions in LiPO2F2, LiDFOP and LiBOB (Chunbo IR decks 2022–2024).

  2. Cost innovation to beat Chinese competitors. Management claimed a new LiFSI process cutting manufacturing cost by more than 50% (Digital Daily, Apr 2023). Research Alum (Aug 2025) cites a lithium-carbonate-based process with savings of at least 30%. Hi Investment (Nov 2023) cites 30–50%. The process is also said to recycle all by-products.

  3. Profitability target. A 25% operating margin target for new lithium-salt products, through cost innovation and process optimization (Quartr Q2 2024 and Q3 2025 summaries; Kiwoom, Jul 2024).

  4. Geographic diversification. Grow the US and Europe to 60% of revenue (target stated Aug 2023). This has not been achieved.

  5. Supplying non-Chinese supply chains. Position as a non-Chinese source of lithium salts and additives for North American supply chains. The Feb 2026 three-way cooperation with Dongwha Electrolyte and PGT is the formal expression (Digital Daily, 10 Feb 2026).

  6. Diversified fine-chemical base. Keep electronic materials, pharma and fine chemicals as stable profit pools (Naver/AI report, May 2026).

Initiatives in the last 24 months

InitiativeDateDetailSource
6th-series CB and KRW 100bn hybrid capitalQ4 2024Refinanced the 2022 CB/BW put; strengthened equity through the hybridValueline/DataHero; Quartr
Chunbo BLS external capital (1)Jul 2025Reported KRW 150bn CB subscription by a Mirae Asset Venture Investment fund (SKS-Mirae Asset corporate restructuring PEF)IB Tomato (24 Jul 2025)
Chunbo BLS external capital (2)Jun 2026KRW 78.2bn CB from Mirae Asset Renaissance New Energy PE; KRW 54.7bn earmarked for facilitiesIB Tomato (9 Jun 2026)
North American LiFSI supplyFrom early 2026F-electrolyte for a North American OEM's in-house 4680 cells (Cybercab), per Mirae AssetHelloT (13 Apr 2026)
North American supply-chain alliance10 Feb 2026With Dongwha Electrolyte and PGT, linking LiPF6 (PGT), salt-based additives (Chunbo) and finished electrolyte (Dongwha, Tennessee)Digital Daily (10 Feb 2026)
Price pass-through2025–2026Customer negotiations to pass through LiPF6 and lithium increases from Q1 2026; about 20% pass-through expected from H2 2026Kiwoom (Jan 2026); Mirae Asset (Apr 2026)
Saemangeum ramp2,026LiFSI and FEC lines contributing revenue; losses continue on fixed costsKiwoom (Aug 2026)

ESG commitments. No formal emissions targets or sustainability-linked financing were identified.

Cost programs. No quantified group cost-reduction program was found beyond the process-cost claims above.

Medium-term targets and guidance

No formal numerical revenue or profit guidance for 2026–2027 was found in the sources reviewed. Historical aspirational targets:

  • KRW 400bn+ revenue for 2023 (CFO, Apr 2023). Actual: KRW 182.7bn.

  • Saemangeum to make Chunbo BLS "a KRW 1 trillion annual-revenue company" (Lee Sang-yul, Jul 2021).

  • LiFSI revenue plan of KRW 58bn → 154bn → 800bn → 2.4tn over ten years (2Q21 IR).

These targets have proved far too optimistic. They should be treated as aspirations, not guidance.

Products & Services

The company does not publish prices. Launch years are given where IR material states them.

Secondary-battery materials

ProductAbbrev. / internal nameFunction / capabilityTarget customerStatus / yearSource
Lithium bis(fluorosulfonyl)imideLiFSI ("F-electrolyte")Specialty lithium salt with higher conductivity and thermal and hydrolytic stability than LiPF6 and better low-temperature performance. Used with high-nickel cathodes, silicon anodes, high-spec ESS and long-warranty IT cells. Used as co-salt or additive.Cell makers, electrolyte formulators; North American OEM (2026)Commercialized 2016/2017 (first worldwide); Saemangeum lines ramping 2026Research Alum via Asia Economy (25 Aug 2025); Chunbo IR 2024
Lithium difluorophosphateLiPO2F2 ("P-electrolyte")Film-forming salt additive improving cycle life and high-voltage performance in NCM cells. Chunbo's flagship product; Korean LiPO2F2 export data are used as a proxy for its revenue.Cell makers (Korean and Chinese, incl. CATL, EVE Energy)Mass production; new-process plant planned (2024 IR); +30% QoQ volume in Q2 2026 (est.)iM Securities (2025); Kiwoom (Aug 2026)
Lithium difluoro(oxalato)phosphateLiDFOP ("D-electrolyte")Salt additive for interphase stabilityCell makersCommercialHi Investment (Jan 2024)
Lithium bis(oxalato)borateLiBOB ("B-electrolyte")Salt additive for high-temperature and cathode protectionCell makersCommercialHi Investment (Jan 2024); Chunbo 4Q21 IR deck
Vinylene carbonateVCSEI-forming anode additiveElectrolyte makers6,000 t VC/FEC mass production planned for Q3 2023Yuanta (Apr 2023)
Fluoroethylene carbonateFECSEI additive, important for silicon anodesElectrolyte makersSaemangeum FEC volumes contributing in 2026Kiwoom (Aug 2026)
1,3-Propane sultonePSSulfur-based SEI and CEI additiveElectrolyte makers4,000 t planned at Gunsan (Saemangeum)Chunbo 2Q23 IR deck
Ethylene sulfate (inferred)ESASulfate film-forming additiveElectrolyte makersListed in IR item listChunbo 1Q23 IR (BofA conference)
Tris(trimethylsilyl) borateTMSBCathode-protective additiveElectrolyte makersCommercial (2021)TheElec (Jan 2021)
Nitrile additivesAN, SN, DPNAdditives suppressing swelling and overchargeElectrolyte makersCommercial (2021)TheElec (Jan 2021)
LiFSI electrolyte Al-corrosion inhibitor—Additive that offsets LiFSI's aluminium-collector corrosionElectrolyte formulatorsDevelopment / portfolioChunbo 2Q24 IR deck
CNT slurry (anode additive)—Conductive additiveCell makersIR (Aug 2022) targeted 1Q 2025Chunbo 2Q22 IR deck
Solid-electrolyte materialsLLZO oxide; polymer electrolytesNext-generation research—R&DChunbo 2Q24 IR deck
ItemDetailSource
Total electrolyte capacity, 20201,840 tTheElec (Jan 2021)
Total capacity 2022 → 2023 plan4,700 t → 17,000 tYuanta (Apr 2023)
LiFSI plan (Aug 2022 IR)1,000 → 5,000 → 5,000 → 10,000 → 21,000 (staged 2022–2026)Chunbo 2Q22 IR deck
LiFSI plan (Aug 2023 IR)10,000 → 20,000 → 20,000 → 50,000 (Gunsan Saemangeum)Chunbo 2Q23 IR deck
LiPO2F2 plan3,000 → 5,000 by 2026Chunbo 2Q23 and 4Q21 IR decks
CFO target (Apr 2023)LiFSI capacity 10,000 t → 50,000 t through 2025 and 2027 expansions; 60% LiFSI market share targetDigital Daily (30 Apr 2023)

The company claims "the largest number of electrolyte additive items globally" (Komachine).

Capacity disclosures (plans, tonnes per year). These are historical plans, and several were delayed.

Kiwoom (Aug 2026) describes Saemangeum utilization as low, with fixed-cost absorption still negative.

Electronic materials

ProductFunctionCustomersNotesSource
LCD etchant additivesAdditives for high-definition LCD etchingPanel makers, etchant formulatorsOriginal core business (2008)Chunbo IR 2020–2022
OLED common-layer materials (e.g., H-369, H-668)Hole and common-layer materialsOLED panel supply chainSince 2013Chunbo 3Q22 and 1Q23 IR decks
OLED emitting-material intermediatesHigh-purity intermediatesOLED material makers—Naver/AI report (May 2026)
Semiconductor fine-pattern and cleaning materialsProcess chemicalsChip supply chainSince 2011Chunbo 3Q22 IR deck
Oxalic acidSemiconductor and industrial usesKorean chipmakers; exports to Japan and TaiwanDescribed as Korea's only producerInnoforest
EMC resin raw materialsSemiconductor packagingPackaging-material makers—Company description (StockHub)
Chemically strengthened glass materialsDisplay cover glassGlass processors—Company description (StockHub)

Fine chemicals and pharmaceutical materials

ProductFunctionNotesSource
5-Aminotetrazole (ATZ)Specialty intermediateDescribed as global #1 producerInnoforest; Naver/AI report (May 2026)
Tire additivesSpecialty chemicals—Company description
Pharmaceutical raw materials and intermediatesCustom synthesisAbout 3% of revenue (Q2 2026)Butler; company description

Financial Narrative

Units are KRW bn unless stated. FY = calendar year. The sources are OpenDART-derived aggregators (Butler, Valueline/DataHero, Bullstory), Quartr earnings summaries and broker reports, as noted. Where sources conflict, both figures are shown.

Income statement — core series

Sources: Butler (OpenDART) for revenue, OP and NI for FY2021–FY2025. FY2021 growth is derived from FY2020 revenue of KRW 155.5bn (TheElec). Margins are derived. Bullstory (OpenDART) confirms FY2025 revenue of KRW 133,849,589,627, OP of KRW 3,710,962,944 and net loss of KRW 60,014,543,541.

Revenue CAGR FY2021–FY2025: –16.2% per year (derived). Revenue in FY2025 was 49% of FY2021 and 41% of the FY2022 peak.

Income statement — additional lines

Notes on this table:

  • It is shown as 0 only as a placeholder for charting and should be treated as not disclosed in sources reviewed.

EPS FY2025: Valueline shows –5,550; Quartr's Q4 2025 summary shows –5,752. The difference likely reflects weighted-average share counts during CB conversions. Both are shown.

Sources: EPS FY2022: Hanwha (May 2024). EPS FY2023–FY2024 and owners' NI: Kiwoom (Jan 2026). Pre-tax FY2023–FY2024: Kiwoom. EBITDA FY2022–FY2023: Hanwha and Kiwoom. FY2024 EBITDA: Kiwoom. FY2025 EBITDA is derived as OP 3.7 + D&A 22.8 (Valueline cash-flow statement); Kiwoom's January 2026 estimate was 25.4.

Interpretation of FY2025. The KRW 63.7bn gap between operating profit (+3.7bn) and the net loss (–60.0bn) is mostly non-cash:

  • Net derivative losses of about KRW 46.6bn, consistent with fair-value remeasurement of CB conversion features as the share price rose about 35% in 2025 (Kiwoom: 1-year return +35.2% to 30 Dec 2025).

  • Interest expense of KRW 22.6bn, against cash interest paid of only KRW 4.9bn per the cash-flow statement. Most interest is accretion on mezzanine instruments.

The reported net loss therefore overstates cash economic losses. It does, however, signal continuing equity dilution, because conversions feed directly into share count.

Quarterly trajectory

Sources: Q1 2025 (Quartr; iM 30 May 2025); Q2 2025 derived from H1 2025 (revenue 68.6, OP 5.7; Quartr); Q3 2025 (iM, 21 Nov 2025); Q4 2025 derived as FY2025 minus 9M 2025 (9M revenue 99.3, 9M OP 6.3; Quartr); Q1 2026 (Quartr); Q2 2026 (Kiwoom via StockHub, 27 Aug 2026). Q4 2025 OP of –2.6bn is derived; Kiwoom had previewed +0.9bn.

H1 2026: revenue KRW 91.8bn (+34% YoY, derived); operating loss KRW 7.2bn; net loss about KRW 12.3bn; cash KRW 16.0bn (Quartr Q2 2026 summary). Quartr's headline describes H1 2026 revenue as "down 31%" and compares the net loss with KRW 32.3bn. Both appear to be errors: the 32.3bn is the FY2024 full-year loss, and H1 2025 revenue was KRW 68.6bn.

Balance sheet

Source: Valueline/DataHero (DART-based). Total debt, short/long split, net debt and working capital are derived.

Definitions and caveats:

Total debt: excludes lease liabilities and the KRW 100bn of hybrid securities, which are classified as equity. If the hybrid is counted as debt, FY2025 adjusted net debt is about KRW 321.8bn.

  • Quartr reports a net debt-to-capital ratio of 43.0% (FY2025) and 44.7% (H1 2026).

Balance-sheet commentary:

Investment cycle: From FY2022 to FY2024, PP&E more than doubled (KRW 341.6bn → 705.1bn) as Saemangeum construction in progress peaked at KRW 549.3bn. In FY2025, KRW 376bn of construction in progress moved into service: building assets rose from KRW 41.3bn to 157.4bn and "other" PP&E from 46.6bn to 244.1bn. This drives the step-up in depreciation (COGS depreciation from KRW 18.9bn to 35.0bn on a TTM basis by Jun 2026).

Liquidity has thinned: Cash plus short-term instruments fell from KRW 266bn (FY2022) to KRW 49.5bn (FY2025), as short-term deposits funded the Q4 2024 CB/BW put redemptions and capex.

Refinancing risk is high: The current ratio is 0.39–0.45x and working capital is negative at KRW –194bn to –211bn. About 84% of financial debt is classified as current at H1 2026, partly because the 6th-series CB is classified as current (derived).

Equity has been rebuilt through conversions, not earnings: Share premium rose from KRW 86.4bn (FY2024) to KRW 238.3bn (H1 2026). Retained earnings fell from KRW 218.6bn (FY2022) to KRW 75.3bn (H1 2026).

Goodwill is zero: and intangibles are negligible. The asset base is almost entirely tangible manufacturing assets.

Cash flow

Sources: Valueline/DataHero (DART-based); Bullstory confirms FY2025 OCF of KRW 8.03bn. Valueline shows its own FCF of KRW –9.4bn on a different definition.

Trailing 12 months to March 2026: OCF KRW 6.4bn, capex KRW 25.5bn (Valueline).

  • Rolling data imply that heavy capex continued through 2024: trailing-12-month capex to March 2025 was KRW 97.7bn. The FY2021–FY2023 build-out was funded by the KRW 300bn 2022 CB/BW and bank borrowings.

Investing inflows in FY2025: reflect redemption of short-term deposits, not divestitures.

Financing outflows in FY2025: include KRW 80.6bn of bond repayment.

Ratio analysis

Calculation notes:

ROE: FY2022 and FY2023 match Hanwha (11.9%, –13.1%). FY2024 and FY2025 are derived from owners' NI over average owners' equity. Quartr reports –9.8% (FY2024) and –15.2% (FY2025); Valueline shows –14.29% TTM.

Asset turnover: Computed on the same asset basis as ROA.

Trend commentary. The five years divide into two phases:

  1. FY2021–FY2022 (expansion). Revenue grew sharply, operating margins were 17–19%, and leverage was low because CB proceeds were still held as deposits.

  2. FY2023–FY2025 (contraction and refinancing). Lithium-linked price deflation halved revenue in FY2023. Delays at Saemangeum held back volumes. The Q4 2024 put window forced refinancing into a lower-strike CB, KRW 100bn of hybrid capital, and short-term bank lines.

The inflection in FY2025 was operational: OP turned positive on cost control and product mix. It was not financial. In 2026, revenue is growing again (Q2 2026 +54% YoY) but margins are negative while new assets depreciate at low utilization. On EBITDA, the business generated about KRW 26–27bn in FY2025 and TTM June 2026. That is enough to cover cash interest but not capex plus debt amortization without outside capital.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRoleOwnership / notesSource

Chunbo Co., Ltd.

Listed parent; electronic materials, fine chemicals, pharma intermediates, legacy battery materials (Chungju)

Lee Sang-yul and related parties 55.9%

Kiwoom (Jan 2026)

Chunbo BLS Co., Ltd. (천보비엘에스)

Saemangeum (Gunsan) LiFSI, additive and lithium-salt complex

Subsidiary. On full conversion of external CBs, outside holders could reach up to ~26% (per IB Tomato). Co-CEOs: Lee Sang-yul and Kim Hyun-ho.

IB Tomato (9 Jun 2026); TheVC

Chunbo Advanced Materials (천보신소재)

Battery-material capacity and new-process development; IR names its site "Yeongpyeong" (영평)

—

Chunbo 2Q24 IR deck (Sep 2024)

Chunbo Precision (천보정밀)

Group company referred to in the IR history slide

—

Chunbo 2Q23 and 2Q24 IR decks

Associate(s)

Equity-method investment of KRW 4.35bn (Jun 2026)

—

Valueline/DataHero

Revenue by Segment

SegmentFY2024FY2025

Secondary battery materials (KRW Bn)

77.267.9

Electronic materials (KRW Bn)

49.051.4

Pharma + fine chemicals + other (KRW Bn)

18.714.5

Total revenue (KRW Bn)

144.9133.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment share of revenue (%)

Segment share of revenue (%)FY2024FY2025

Secondary battery materials (%)

53.350.7

Electronic materials (%)

33.838.4

Pharma + fine chemicals + other (%)

12.910.8

Segment Revenue

SegmentFY2022 basis (reported Apr 2023)Q2 2026

Secondary battery materials

68.058

Electronic materials

23.829

Other

4.08

Fine chemicals

2.42

Pharmaceutical materials

1.83

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

271.6328.9182.7144.9133.8

Operating income (KRW Bn)

50.656.5-8.0-22.83.7

Net income incl. NCI (KRW Bn)

48.042.8-45.5-32.3-60.0

Revenue growth YoY (%)

74.721.1-44.5-20.7-7.6

Operating margin (%)

18.617.2-4.4-15.72.8

Net margin (%)

17.713.0-24.9-22.3-44.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025

Net income attributable to owners (KRW Bn)

37.4-41.8-27.4-57.8

Basic EPS (KRW)

3,736-4,175-2,740-5,550

Pre-tax income (KRW Bn)

0-42.4-27.7-62.8

EBITDA (KRW Bn)

76.011.7-3.226.5

Business Lines

Line (FY2025)KRW Bn

Revenue

133.85

Cost of sales

120.41

— of which raw materials

55.42

— of which labour

10.65

— of which depreciation

21.76

Gross profit

13.43

SG&A

9.72

— of which R&D expense (in SG&A)

1.27

Operating income

3.71

Financial income

15.65

— of which derivative gains

12.20

Financial costs

81.35

— of which interest expense

22.60

— of which derivative losses

58.75

Other non-operating, net

-1.67

Pre-tax loss

-62.83

Income tax (benefit)

-2.81

Net loss

-60.01

Net loss attributable to owners

-57.77

Gross Margin by Period

PeriodGross marginSource

FY2025

10.0% (derived)

Valueline

9M 2024

Gross loss of KRW 14.1bn

Quartr Q3 2025 summary

9M 2025

13.3%

Quartr Q3 2025 summary

H1 2025

15.1%

Quartr Q2 2026 summary

H1 2026

–3.3% (start-up depreciation at Saemangeum)

Quartr Q2 2026 summary

TTM to Jun 2026

Essentially zero gross profit (KRW 0.01bn)

Valueline

Income Statement

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue (KRW Bn)

35.633.030.634.640.851.0

Operating income (KRW Bn)

2.82.90.6-2.6-3.4-3.8

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025H1 2026

Total assets (KRW Bn)

818.7933.71,007.9849.5907.9

Current assets (KRW Bn)

439.4281.9247.4125.9169.2

Cash & equivalents (KRW Bn)

64.860.815.915.516.0

Short-term financial instruments (KRW Bn)

201.2111.0160.534.040.6

Trade receivables (KRW Bn)

57.525.624.126.440.2

Inventories (KRW Bn)

86.169.332.431.254.2

PP&E (KRW Bn)

341.6612.3705.1652.2650.2

Construction in progress (KRW Bn)

175.1448.1549.3173.2137.5

Goodwill (KRW Bn)

00000

Intangible assets (KRW Bn)

1.11.00.81.41.3

Total liabilities (KRW Bn)

423.8583.2592.9382.2425.5

Current liabilities (KRW Bn)

148.4233.4489.8320.3379.9

Short-term borrowings (KRW Bn)

48.0152.0127.596.899.3

Short-term bonds incl. current CB (KRW Bn)

13.05.6174.774.691.1

Current portion of LT borrowings (KRW Bn)

9.58.546.539.535.4

Convertible bonds non-current (KRW Bn)

212.2220.8000

Bonds with warrants non-current (KRW Bn)

42.444.2000

Long-term borrowings (KRW Bn)

19.883.3101.460.443.2

Total debt (KRW Bn)

344.9514.4450.1271.3269.0

Short-term debt (KRW Bn)

70.5166.1348.7210.9225.8

Long-term debt (KRW Bn)

274.4348.3101.460.443.2

Cash + ST financial instruments (KRW Bn)

266.0171.8176.449.556.6

Net debt (KRW Bn)

78.9342.6273.7221.8212.4

Total equity (KRW Bn)

394.8350.5414.9467.4482.4

Equity attributable to owners (KRW Bn)

343.1296.6365.9423.5452.0

Hybrid capital securities in equity (KRW Bn)

00100.0100.0100.0

Non-controlling interests (KRW Bn)

51.854.049.043.830.4

Working capital, CA minus CL (KRW Bn)

291.048.5-242.4-194.4-210.7

Book value per share (KRW)

34,30829,65736,59036,23036,886

Shares outstanding (millions)

10.0010.0010.0011.6912.25

Cash Flow

MetricFY2025

Operating cash flow (KRW Bn)

8.0

Capex, PP&E acquisitions (KRW Bn)

21.5

Free cash flow, OCF minus capex (KRW Bn)

-13.5

Investing cash flow (KRW Bn)

151.0

Financing cash flow (KRW Bn)

-159.4

Dividends paid (KRW Bn)

0

Share buybacks (KRW Bn)

0

Interest paid (KRW Bn)

4.9

D&A (KRW Bn)

22.8

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE (%)

11.9-13.1-8.3-14.6

ROA (%)

5.2-5.2-3.3-6.5

Current ratio (x)

2.961.210.510.39

Debt to equity (x)

0.871.471.080.58

Asset turnover (x)

0.400.210.150.14

Financial Ratios (x) and Margin Analysis (%)

RatioFY2022FY2023FY2024FY2025Note

Net debt / EBITDA

~1.0x

~29x

n/m (negative EBITDA)

~8.4x

Derived

Interest coverage (OP / interest expense)

—

negative

negative

~0.16x

FY2025: 3.7 / 22.6

ROIC (NOPAT / [equity + net debt])

—

negative

negative

~0.4%

FY2025, assumes 20% tax on OP

Cash conversion cycle

———

~151 days

FY2025 DSO ~72, DIO ~95, DPO ~16 (year-end balances)

Gross margin

———10.0%—

EBITDA margin

23.1%6.4%-2.2%19.8%

Derived

Region / Indicator Details

Region / indicatorData pointDate / basisSource

China share of revenue

About 40%

2022–2023

Dealsite (22 Aug 2023); DS Investment (8 Jun 2023)

Management target

Cut China to 20% and raise Europe and US to 60% by end-2024

Stated Aug 2023

Dealsite (22 Aug 2023)

Outcome vs target

Not achieved. Europe and US electrolyte demand stayed weak; China share rose in Q4 2025.

Jan 2026

Kiwoom (2 Jan 2026)

China (Q4 2025 → 2026)

LiPO2F2 shipments rising, led by EVE Energy; Chinese demand and prices drove +30% QoQ LiPO2F2 volume in Q2 2026

Q4 2025 – Q2 2026

Kiwoom (Jan and Aug 2026)

North America

LiFSI shipments to a North American OEM since early 2026; LiFSI revenue estimated at KRW 1.3bn (Q1 2026) and KRW 3.6bn (Q2 2026)

2026

Mirae Asset (Apr 2026); Kiwoom (Aug 2026)

Korea

Electronic materials and oxalic acid sold mainly to Korean panel and chip supply chains; Korean cell makers for battery materials

Ongoing

Company descriptions

Japan and Taiwan

Oxalic-acid exports

Ongoing

Innoforest

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

218,300110,20036,35049,150

Year-end market cap (KRW Bn)

2,183.01,102.0363.5572.1

Year-end price to book (x)

6.43.720.991.35

Share Price History

DatePriceSource

2 Mar 2023

244,000

Yuanta

10 Apr 2023

281,500

Yuanta

29 Nov 2023

108,400

Broker report

17 May 2024

76,500

Hanwha

13 Nov 2024

44,950

iM

29 May 2025

35,650

iM

20 Nov 2025

55,900

iM

30 Dec 2025

49,150

Kiwoom

18 May 2026

50,600

Naver/AI report

30 Jun 2026

40,700

Valueline

4 Aug 2026

32,950

Valueline

16 Oct 2026

34,150

Valueline

19 Oct 2026

36,550

Valueline

Valuation Snapshot

MultipleValueBasis

Market cap

~KRW 448bn

12.25m shares

P/E (TTM)

Negative / n.m.

TTM owners' net loss about KRW 64.6bn (Valueline, Jun 2026)

P/B

~0.99x

BPS KRW 36,886 (Jun 2026, includes hybrid in owners' equity). Valueline shows 0.92x on its own market cap.

EV

~KRW 691bn

Market cap 448 + debt 269.0 – cash and short-term instruments 56.6 + NCI 30.4. About KRW 791bn if the KRW 100bn hybrid is treated as debt.

EV / Sales (TTM)

~4.4x (about 5.0x with hybrid as debt)

TTM revenue KRW 157.0bn

EV / EBITDA (TTM)

~26x (about 30x with hybrid)

TTM EBITDA about KRW 26.8bn (OP –9.2 + D&A 36.0)

Mirae Asset framework

15x EV/EBITDA on 2027E

HelloT (Apr 2026)

iM framework

P/E about 23–26x on 2027E

iM (May 2025: 23.3x; Nov 2025: 26.0x)

Analyst Ratings & Targets

BrokerDateRatingTarget price (KRW)Key estimatesSource

Mirae Asset Securities

13 Apr 2026

Buy

79,000 (from 68,000)

2026E OP –KRW 3.0bn; F-product 36% (2026) and 46% (2027) of revenue; 15x 2027E EV/EBITDA

HelloT

Kiwoom Securities

Jul 2026 (2Q26 preview)

Outperform

45,000

2Q26 revenue KRW 48.5bn, OP –KRW 3.0bn

StockHub

Kiwoom Securities

27 Aug 2026

Not stated

Not stated

Q4 2026 turnaround expected

StockHub

Kiwoom Securities

2 Jan 2026

Marketperform

52,000

2026F revenue KRW 192.6bn, OP KRW 3.7bn; 2027F OP KRW 25.6bn

Kiwoom; Aju News

iM Securities

21 Nov 2025

Not stated in excerpt

Not stated in excerpt

2026E revenue KRW 214.6bn, OP KRW 11.5bn

iM

iM Securities

30 May 2025

Not stated in excerpt

40,000

2025E revenue KRW 166.7bn, OP KRW 13.5bn

iM

Consensus (5 brokers)

Date not stated

—51,000—

Butler

Consensus (latest 90 days)

Oct 2026

—

45,000 (1 report)

—

StockHub

Bucket Details

BucketKRW Bn

Short-term borrowings

99.3

Short-term bonds (incl. current CB)

91.1

Current portion of LT borrowings

35.4

Total due ≤12 months

225.8

Long-term borrowings

43.2

Analyst Conclusions

Management guidance and consensus

No formal numerical guidance was found. Management's stated direction:

  • reach a 25% operating margin on new lithium salts through process innovation;

  • scale LiFSI for North American customers;

  • recover pricing through raw-material pass-through.

Sell-side expectations range widely. Kiwoom forecasts a 2026 operating profit of KRW 3.7bn (January) and expects a Q4 2026 turnaround (August). Mirae Asset forecasts an operating loss of KRW 3.0bn for 2026 but strong EBITDA growth into 2027. iM had forecast KRW 11.5bn (November 2025). H1 2026 actual operating profit was –KRW 7.2bn, so full-year 2026 operating profit near breakeven or negative is the realistic base case. FY2027 forecasts are the main valuation anchor (Kiwoom 2027F OP KRW 25.6bn; Mirae Asset 15x EV/EBITDA on 2027E).

Bull case (grounded in data)

  1. LiFSI volume step-change. LiFSI revenue nearly tripled QoQ (KRW 1.3bn → 3.6bn) between Q1 and Q2 2026. If F-products reach 36–46% of revenue as Mirae Asset projects, utilization at the KRW 650bn asset base rises and EBITDA margins should rise sharply on fixed-cost leverage.

  2. Sector tailwind. Chinese peers are near full utilization (Tinci H1 2026 net profit +968%). Tight salt and electrolyte markets plus LiPF6 price increases support ASP recovery and about 20% raw-material pass-through from H2 2026.

  3. Valuation on assets. At about 0.99x P/B and roughly KRW 450bn market cap against KRW 650bn of mostly new PP&E, the market pays little for replacement value. The capex cycle has largely ended (construction in progress down 68% in FY2025), so the free-cash-flow profile can improve quickly if utilization rises.

Bear case (grounded in data)

  1. Earnings quality and dilution. Net losses have continued for three years (–KRW 60.0bn in FY2025). About 2.34m further shares from CB conversion (about 19%) and potential minority dilution at Chunbo BLS (up to about 26%) limit per-share upside even if operations recover.

  2. Liquidity. A 0.39x current ratio, KRW 225.8bn of debt due within 12 months, and FY2025 OCF of only KRW 8.0bn mean the company depends on continuous refinancing. The August 2026 collateral-provision filing and the subsidiary CB terms (IPO deadline, EBITDA reset) add contingent pressure.

  3. Structural competitive disadvantage. The 2026 upcycle is lifting Chinese scale players far faster than Chunbo (H1 revenue +109% at Tinci vs +34% at Chunbo, which is still loss-making). The non-China premium remains uncertain under current US policy, and the LiFSI ramp depends on a single OEM program.

Catalysts and monitorables (next 12 months)

  1. Q3 2026 results (expected mid-November 2026). Gross margin back to positive? Progress toward the Q4 turnaround Kiwoom expects.

  2. Quarterly LiFSI revenue. Can it exceed about KRW 10bn per quarter (implied by the 36% F-mix target)? Disclosure of Saemangeum utilization.

  3. Korean LiPO2F2 export data (KITA) as a monthly real-time proxy.

  4. LiPF6 and lithium carbonate prices, and contract pass-through outcomes.

  5. Remaining conversion of the KRW 101.9bn 6th-series CB, and any new mezzanine issuance at the parent.

  6. Chunbo BLS IPO preparation and compliance with CB covenants.

  7. US policy: FEOC rules for components, and any duties on China-origin electrolyte salts.

  8. Volume of the North American OEM's 4680 / Cybercab program.

  9. FY2026 annual report (Mar 2027): debt refinancing, hybrid terms, derivative remeasurement.

  10. Insider and major-shareholder filings (follow-ups to the Jul–Aug 2026 reports).

Analyst verdict

Chunbo is a high-quality chemistry business attached to a strained balance sheet, and its main investment has not yet earned a return. Its technical claims hold up: it commercialized LiFSI first, it remains a reference supplier of LiPO2F2, and its electronic-materials franchise still produces roughly KRW 50bn a year at about 20% margins. The difficulty is financial and structural, not technological. Between 2021 and 2025 the company invested roughly KRW 650bn of assets into a market that Chinese producers then oversupplied. Delays at Saemangeum meant its new capacity arrived after prices had collapsed.

The 2026 situation has improved. Quarterly revenue has risen for three straight quarters to KRW 51bn. LiFSI is shipping to a North American OEM. The capex cycle is largely complete. Chinese peers' results show the electrolyte chain is in a genuine upcycle. On about 0.99x book value, the market is not pricing in success.

However, the improvement has not yet reached reported earnings. Gross margin was negative in H1 2026, interest costs exceed operating profit, and every equity rebuild since 2024 has come through conversions that dilute minorities. With about 19% more parent dilution outstanding and contingent claims at the Chunbo BLS level, value created by the turnaround will be shared heavily with mezzanine holders.

On balance, Chunbo is a speculative, catalyst-driven turnaround, not a quality compounder. The key evidence to watch is whether quarterly LiFSI revenue reaches double-digit KRW billions and gross margin returns to 15% or more before the next refinancing window. If both happen by mid-2027, FY2027 EBITDA in the KRW 60–80bn range becomes plausible and current multiples are undemanding. If they do not, the balance sheet will force another dilutive financing at a lower price. Position sizing should reflect a wide range of outcomes. Investors should wait for the Q3 and Q4 2026 results to confirm the turnaround Kiwoom expects rather than buy ahead of it.


SOURCES CONSULTED (selection)

Chunbo IR presentations: 2Q21 (Aug 2021), 4Q21 (Feb 2022), 2Q22 (Aug 2022), 3Q22 (Nov 2022), 1Q23 (Apr 2023; BofA conference May 2023), 2Q23 (Aug 2023), 2Q24 (Sep 2024)

Earnings summaries: Quartr Chunbo summaries (Q2 2024 – Q2 2026); Quartr Enchem summaries

DART-based financial aggregators: Valueline/DataHero balance sheet, income statement and cash flow (accessed 19 Oct 2026); Butler.works (OpenDART); Bullstory (OpenDART)

Broker research: - Kiwoom Securities: 8 Jul 2024; 2 Jan 2026; 2Q26 preview; 27 Aug 2026 via StockHub

  • iM / Hi Investment & Securities: Nov 2023, Jan 2024, mid-2024, Nov 2024, 30 May 2025, 21 Nov 2025

  • Mirae Asset Securities (via HelloT, 13 Apr 2026)

  • Daishin (Mar 2022, Aug 2022, Jul 2023); Yuanta (Mar and Apr 2023); Hanwha (May 2024); DS Investment (Jun 2023)

  • Research Alum (via Asia Economy, 25 Aug 2025)

  • Naver AI company report (20 May 2026)

Press: - IB Tomato: 2 May 2023; 24 Jul 2025; 9 Jun 2026

  • Dealsite: 25 Apr 2023; 22 Aug 2023

  • Digital Daily: 30 Apr 2023; 10 Feb 2026

  • MTN: 12 Oct 2022

  • TheElec: 25 Jan 2021

  • Newsis and Jeonbuk Ilbo: 7 Jul 2021

  • Asia Economy and Energy Economy: 8 Oct 2018

  • Aju News: 2 Jan 2026

  • Edaily via Techleap: Jan 2026

Industry context: Mysteel (Tinci and Capchem H1 2026, 21 Aug 2026; EVE–Fluence, 18 Sep 2026; China battery data); Tiger Brokers (Capchem FY2025); MarketGrowthReports (LiFSI penetration; low-confidence source)

Company profiles: Komachine, Innoforest, TheVC, Craft.co, Koalagains, StockHub

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / roleCompensation

Lee Sang-yul (이상율)

CEO and Representative Director; founder and controlling shareholder; also CEO of Chunbo BLS

CEO since at least listing (2019). Led the company through the LiFSI commercialization.

Not publicly disclosed in sources reviewed (Korean individual pay disclosure applies only above KRW 500m)

Lee Dong-ho (이동호)

CFO / Executive Director (전무)

Public IR spokesman (2023)

—

Kim Hyun-ho (김현호)

Co-CEO, Chunbo BLS

Current (TheVC listing)

—

“—” = not publicly disclosed.

Major Shareholders

HolderStakeDateSource

Lee Sang-yul and 11 related parties

55.9%

Dec 2025 / Jan 2026

Kiwoom (2 Jan 2026)

Lee Sang-yul and related parties (earlier)

55.4%

2023–2024

Hanwha (May 2024); DS (Jun 2023)

Treasury shares

0.56% to 0.7%

2024–2026

Butler; Hanwha

Foreign ownership

2.1%

Dec 2025

Kiwoom (Jan 2026)

Foreign ownership (earlier)

9.30% (Mar 2023) → 5.1% (Nov 2024)

—

Yuanta; iM

Unconverted 6th-series CB holders

Up to about 2.34m shares (about 19% of current shares) at KRW 43,541

Jun 2026

IB Tomato (9 Jun 2026)

Competitive Landscape

Competitors by Segment

SegmentCompetitorCountryRelevance to Chunbo

Lithium salts and additives / electrolyte

Guangzhou Tinci Materials

China

Global electrolyte leader with integrated LiPF6 and LiFSI

Lithium salts and additives / electrolyte

Shenzhen Capchem

China

Electrolyte and additives; Malaysia plant due end-2026

Lithium salts

Do-Fluoride (DFD)

China

LiPF6 and LiFSI

Additives

Huasheng Lithium and other Chinese VC/FEC makers

China

Price setters in VC/FEC

LiFSI

Nippon Shokubai

Japan

LiFSI ("IONEL")

LiFSI

Arkema

France

LiFSI

LiPF6 / salts

Foosung

Korea

Korean fluorine salts (named by Koalagains)

LiPF6

PGT

Korea

Partner since Feb 2026; adjacent rather than direct competitor

Electrolyte (customer and competitor in additives)

Dongwha Electrolyte

Korea

Partner and customer

Electrolyte

Enchem

Korea

Electrolyte; building LiFSI and lithium-salt capability

Electrolyte / electronic materials

Soulbrain

Korea

Also competes in semiconductor chemicals

Electronic chemicals

ENF Technology, Dongwoo Fine-Chem

Korea

Etchants and process chemicals

Peer Comparison FY2025

CompanyLatest revenueGrowthProfitabilitySource

Chunbo

FY2025 KRW 133.8bn; H1 2026 KRW 91.8bn

FY2025 –7.6%; H1 2026 +34%

FY2025 OPM 2.8%; H1 2026 OPM –7.8%; R&D (SG&A) about 0.9%

—

Capchem

FY2025 RMB 9.639bn; H1 2026 RMB 7.463bn

FY2025 +22.84%; H1 2026 +75.66%

FY2025 gross margin 24.28%; H1 2026 net profit RMB 984m

Tiger Brokers (FY2025); Mysteel (21 Aug 2026)

Tinci Materials

H1 2026 RMB 14.71bn

H1 2026 +109.28%

H1 2026 net profit RMB 2.861bn; FY2025 net profit guided at RMB 1.1–1.6bn

Mysteel (21 Aug 2026; 4 Jan 2026)

Enchem

FY2025 KRW 312.8bn; H1 2026 KRW 186.4bn

FY2025 –14.5% vs KRW 365.7bn

FY2025 OP –KRW 78.4bn; going-concern uncertainty flagged

Quartr Enchem Q2 2026 summary

Company Snapshot

$94.2M

Revenue

1997

Founded

Chungju, South Korea

Headquarters

SWOT Analysis

Strengths

  • First-mover LiFSI technology. World-first commercialization (2016/2017), with a claimed new process cutting cost by more than 30–50% and recycling all by-products (Research Alum, Aug 2025; Digital Daily, Apr 2023).
  • A profitable electronic-materials core. Revenue of KRW 51.4bn in FY2025 (+5%) at about 20% operating margin (Quartr; Mirae Asset, Apr 2026).
  • A North American OEM anchor customer. LiFSI shipments since early 2026; LiFSI revenue rose from KRW 1.3bn (Q1) to KRW 3.6bn (Q2 2026) (Kiwoom, Aug 2026).
  • Blue-chip customer base. LGES, Samsung SDI, SK On, CATL, BYD, Panasonic, Tesla (Digital Daily, Apr 2023); EVE Energy (Kiwoom, Jan 2026).
  • A new, largely completed asset base. PP&E of KRW 652bn, with construction in progress cut from KRW 549bn (FY2024) to KRW 173bn (FY2025). Most of the capex is already spent (Valueline).
  • Ability to raise capital. KRW 300bn of mezzanine in 2022, about KRW 300bn of CB and hybrid in Q4 2024, and KRW 78.2bn at Chunbo BLS in 2026, which shows continued institutional appetite (MTN; Valueline; IB Tomato).

Weaknesses

  • Persistent net losses. FY2023 –KRW 45.5bn, FY2024 –32.3bn, FY2025 –60.0bn (Butler).
  • Thin liquidity. Current ratio 0.39x (FY2025); cash plus short-term instruments KRW 49.5bn against KRW 210.9bn of short-term debt (derived).
  • Interest burden. Interest expense of KRW 22.6bn against OP of KRW 3.7bn in FY2025, i.e., about 0.16x coverage (Valueline).
  • Negative gross margin during ramp. H1 2026 gross margin –3.3% (Quartr).
  • Track record of missed targets. 2023 revenue target of KRW 400bn+ vs actual KRW 182.7bn; Saemangeum start slipped from Q4 2023 to Q2 2024 and beyond (Digital Daily; Hi Investment; Kiwoom).
  • Low disclosed R&D. SG&A R&D of only KRW 1.27bn (0.95% of revenue) in FY2025 (Valueline).

Opportunities

  • LiFSI mix shift. Mirae Asset projects F-products at 36% of revenue in 2026 and 46% in 2027 (Apr 2026).
  • Industry upcycle. Tinci H1 2026 revenue +109% and Capchem +76% show strong demand (Mysteel, Aug 2026).
  • Price pass-through. About 20% raw-material pass-through from H2 2026 (Mirae Asset).
  • North American localization. Dongwha Electrolyte's Tennessee plant with PGT and Chunbo inputs (Digital Daily, Feb 2026).
  • Possible US trade measures on China-origin materials (iM, May 2025).
  • Monetizing Chunbo BLS via IPO. The 2026 CB terms require a qualified listing (IB Tomato, Jun 2026).

Threats

  • Chinese overcapacity and price competition in LiFSI and additives (Research Alum, Aug 2025).
  • Dilution. KRW 101.9bn of unconverted 6th-series CB equals about 2.34m shares, roughly 19% of current shares (IB Tomato, Jun 2026).
  • Subsidiary dilution and redemption risk. If the IPO deadline is missed, investors can demand early redemption, and the 2029 EBITDA test of KRW 80bn can reset the conversion price downward (IB Tomato).
  • US policy erosion. Reduced IRA benefits and lenient FEOC treatment of low-value inputs (Kiwoom, Aug 2026; Hi Investment, 2024).
  • Single-program dependence. LiFSI growth depends on one OEM program (Cybercab / 4680) (Mirae Asset).
  • Demand risks from the Chinese NEV tax change (50% exemption in 2026) and weak EU/US electrolyte demand (Kiwoom, Jan 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025Q1 2025: revenue KRW 35.6bn (–10% YoY), OP KRW 2.8bn (back to profit), owners' NI KRW 0.9bn Quartr Q1 2025 summaryFirst clear operating recovery
30 May 2025iM Securities flags a possible 2026 US countervailing duty on China-origin materials, which would benefit Korean LiPO2F2 and LiFSI; TP KRW 40,000 iM (30 May 2025)Policy optionality
24 Jul 2025Report that a Mirae Asset Venture Investment fund will take a KRW 150bn Chunbo BLS CB IB TomatoSubsidiary funding without parent dilution
Aug 2025H1 2025: revenue KRW 68.6bn (–7.9%), OP KRW 5.7bn, net loss KRW 5.4bn; battery segment still loss-making Quartr Q2 2025 summaryRecovery driven by electronic materials
25 Aug 2025Research Alum: 2025E revenue KRW 166.5bn, OP KRW 15.5bn; highlights LiFSI cost advantage Asia EconomyOptimistic third-party view; actual FY2025 well below
Nov 2025Q3 2025: revenue KRW 30.6bn (–18% YoY), OP KRW 0.6bn vs consensus KRW 3.2bn iM (21 Nov 2025)Miss; LiPO2F2 export weight –5% QoQ
21 Nov 2025iM: 2025E revenue KRW 140.5bn, OP KRW 8.7bn; 2026E revenue KRW 214.6bn, OP KRW 11.5bn; price-hike potential vs volume uncertaintyEstimate cuts
Q4 2025LiPO2F2 shipments to EVE Energy rise; China share up Kiwoom (2 Jan 2026)Mix negative but volumes improve
2 Jan 2026Kiwoom raises TP to KRW 52,000 (Marketperform); flags overhang and Saemangeum delays; expects Q1 2026 loss Kiwoom; Aju NewsCautious sell-side stance
Jan 20266th-series CB conversion: KRW 4.3bn → 98,756 shares (0.84%), listed 16 and 30 Jan Edaily via TechleapOngoing dilution
Early 2026LiFSI shipments start to a North American OEM (4680 / Cybercab, per Mirae Asset) Mirae Asset via HelloTKey anchor customer for Saemangeum
10 Feb 2026North American supply-chain cooperation with Dongwha Electrolyte and PGT Digital DailyCommercial pathway into US electrolyte
Mar 2026FY2025: revenue KRW 133.8bn (–7%), OP KRW 3.7bn, net loss KRW 60.0bn; electronic materials +5% to KRW 51.4bn; battery –12% to KRW 67.9bn Quartr Q4 2025 summaryOperating breakeven; non-cash losses
30 Mar 2026Investor relations event held Naver/AI report filing list—
13 Apr 2026Mirae Asset: Buy, TP raised from KRW 68,000 to 79,000; 2027E EBITDA +11%; 15x EV/EBITDA; F-product share of revenue 2% (2025) → 36% (2026) → 46% (2027); 2026E OP –KRW 3.0bn HelloT (13 Apr 2026)Most bullish published view
13 Apr 2026KRX designates Chunbo a short-selling overheating stock (short-sale ban applied) Naver/AI report filing listVolatility and positioning signal
22 Apr 2026Share price peaks around KRW 70,000 Naver/AI report (20 May 2026)Momentum peak
27 Apr, 4 May, 12 May 2026Additional listings from CB conversions; conversion-request filings (with corrections) on 29 Apr Naver/AI report filing listSupply overhang realized
15 May 2026Q1 2026 report: revenue KRW 40.8bn (+14%), OP –KRW 3.4bn, net loss KRW 9.5bn; negative gross margin Quartr Q1 2026 summaryStart-up costs at Saemangeum
18 May 2026Share price KRW 50,600, down 27.7% from the April peak Naver/AI reportDe-rating
5–9 Jun 2026Chunbo BLS issues KRW 78.2bn CB to Mirae Asset Renaissance New Energy PE (IPO deadline; 2029 EBITDA KRW 80bn reset) IB TomatoFunding secured; IPO pressure
Jul 2026Kiwoom 2Q26 preview: Outperform, TP KRW 45,000; revenue KRW 48.5bn, OP –KRW 3.0bn StockHub/KiwoomUpgrade in rating, lower TP
3 Jul and 31 Jul 2026Executive and major-shareholder holding-change reports filed ButlerInsider activity
5 Aug 2026Large-shareholding status report filed ButlerHolder change
13 Aug 2026Board decision to provide collateral for another party Butler–
14 Aug 2026H1 2026 report: Q2 revenue KRW 51.0bn (+25% QoQ, +54% YoY), OP –KRW 3.8bn (consensus –KRW 5.9bn) Kiwoom via StockHub; ButlerBetter than expected; record-scale quarter since 2023
27 Aug 2026Kiwoom: Q4 2026 profit turnaround expected; LiFSI revenue KRW 1.3bn (Q1) and 3.6bn (Q2); LiPO2F2 volume +30% QoQ on Chinese demand and prices StockHub/KiwoomTrough-earnings thesis
–Newsprime headline: Chunbo "begins supplying core material for North American robotaxi" StockHub news listConfirms the Cybercab-linked narrative in the press
19 Oct 2026Shares +8.1% to KRW 36,550 Valueline/DataHeroVolatile; near the low end of the 52-week range

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total revenue fell from KRW 144.9 Bn in FY2024 to KRW 133.8 Bn in FY2025.
Chunbo Co., Ltd. — Revenue by Segment
Series (KRW Bn)FY2024FY2025
Total revenue144.9133.8
Secondary battery materials77.267.9
Electronic materials4951.4
Pharma + fine chemicals + other18.714.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.